New drug tested to fight advanced breast cancer

NCT ID NCT04699630

Completed Disease control Sponsor: SCRI Development Innovations, LLC Source: ClinicalTrials.gov ↗

Summary

This study tested a new drug called U3-1402 in 121 patients whose breast cancer had spread or was locally advanced. The main goal was to see if the drug was safe and if it could shrink tumors or stop the cancer from growing for at least six months. Researchers also looked at how different types of breast cancer, based on specific markers, responded to the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope

Duarte, California, 91010, United States
Florida Cancer Specialists-North

St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists-South

Fort Myers, Florida, 33901, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Highlands Oncology Group

Springdale, Arkansas, 72762, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Rutgers-Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED BREAST CANCER METASTATIC BREAST CANCER